People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Other, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Njoy Inc | — | Other | Series C | $229.0M | $1.2B | 2013 |
| Better Therapeutics, Inc. | — | Biotechnology | Series A | $8.9M | $1.7M | 2023 |
| Healthline Networks Inc | — | Other Technology | Series A | $7.0M | $194.2M | 2010 |
Richard Carmona at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Carmona on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Brown | 1 | 16 |
| David Perry | 1 | 11 |
| Michael Farello | 1 | 7 |
| Richard Harroch | 1 | 4 |
| Geoffrey Parker | 1 | 3 |
| Craig Weiss | 1 | 3 |
| Elder Granger | 1 | 3 |
| Niraj Katwala | 1 | 2 |
| Dean Stephens | 1 | 2 |
| Mark Heinen | 1 | 2 |
| Paul Sheils | 1 | 2 |
| Adam Draizin | 1 | 2 |
| Jeffrey Weiss | 1 | 2 |
| Elie Wurtman | 1 | 2 |
| James Warner | 1 | 2 |
| Douglas Teitelbaum | 1 | 2 |
| West Shell | 1 | 1 |
| Risa Lavizzo-Mourey | 1 | 1 |
| Kristin Wynholds | 1 | 1 |
| Frank Karbe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.